Cargando…
Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
BACKGROUND: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15–18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduc...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519392/ https://www.ncbi.nlm.nih.gov/pubmed/34579975 http://dx.doi.org/10.1016/j.vaccine.2021.09.038 |
_version_ | 1784584439201792000 |
---|---|
author | Aksnes, Brooke Noel Walldorf, Jenny A. Nkwenkeu, Sylvain F. Zoma, Robert L. Mirza, Imran Tarbangdo, Felix Fall, Soukeynatou Hien, Sansan Ky, Cesaire Kambou, Ludovic Diallo, Alpha Oumar Aké, Flavien H. Hatcher, Cynthia Patel, Jaymin C. Novak, Ryan T. Hyde, Terri B. Medah, Isaïe Soeters, Heidi M. Jalloh, Mohamed F. |
author_facet | Aksnes, Brooke Noel Walldorf, Jenny A. Nkwenkeu, Sylvain F. Zoma, Robert L. Mirza, Imran Tarbangdo, Felix Fall, Soukeynatou Hien, Sansan Ky, Cesaire Kambou, Ludovic Diallo, Alpha Oumar Aké, Flavien H. Hatcher, Cynthia Patel, Jaymin C. Novak, Ryan T. Hyde, Terri B. Medah, Isaïe Soeters, Heidi M. Jalloh, Mohamed F. |
author_sort | Aksnes, Brooke Noel |
collection | PubMed |
description | BACKGROUND: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15–18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduction, we assessed the sources and content of immunization information available to caregivers and explored motivations and barriers that influence their decision to seek MACV for their children. METHODS: Twenty-four focus group discussions (FGDs) were conducted with caregivers of children eligible for MACV and MCV2. Data collection occurred in February–March 2018 in four purposively selected districts, each from a separate geographic region; within each district, caregivers were stratified into groups based on whether their children were unvaccinated or vaccinated with MACV. FGDs were recorded and transcribed. Transcripts were coded and analyzed using qualitative content analysis. RESULTS: We identified many different sources and content of information about MACV and MCV2 available to caregivers. Healthcare workers were most commonly cited as the main sources of information; caregivers also received information from other caregivers in the community. Caregivers’ motivations to seek MACV for their children were driven by personal awareness, engagements with trusted messengers, and perceived protective benefits of MACV against meningitis. Barriers to MACV and MCV2 uptake were linked to the unavailability of vaccines, immunization personnel not providing doses, knowledge gaps about the 15–18 month visit, practical constraints, past negative experiences, sociocultural influences, and misinformation, including misunderstanding about the need for MCV2. CONCLUSIONS: MACV and MCV2 uptake may be enhanced by addressing vaccination barriers and effectively communicating vaccination information and benefits through trusted messengers such as healthcare workers and other caregivers in the community. Educating healthcare workers to avoid withholding vaccines, likely due to fear of wastage, may help reduce missed opportunities for vaccination. |
format | Online Article Text |
id | pubmed-8519392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-85193922021-10-21 Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018 Aksnes, Brooke Noel Walldorf, Jenny A. Nkwenkeu, Sylvain F. Zoma, Robert L. Mirza, Imran Tarbangdo, Felix Fall, Soukeynatou Hien, Sansan Ky, Cesaire Kambou, Ludovic Diallo, Alpha Oumar Aké, Flavien H. Hatcher, Cynthia Patel, Jaymin C. Novak, Ryan T. Hyde, Terri B. Medah, Isaïe Soeters, Heidi M. Jalloh, Mohamed F. Vaccine Article BACKGROUND: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15–18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduction, we assessed the sources and content of immunization information available to caregivers and explored motivations and barriers that influence their decision to seek MACV for their children. METHODS: Twenty-four focus group discussions (FGDs) were conducted with caregivers of children eligible for MACV and MCV2. Data collection occurred in February–March 2018 in four purposively selected districts, each from a separate geographic region; within each district, caregivers were stratified into groups based on whether their children were unvaccinated or vaccinated with MACV. FGDs were recorded and transcribed. Transcripts were coded and analyzed using qualitative content analysis. RESULTS: We identified many different sources and content of information about MACV and MCV2 available to caregivers. Healthcare workers were most commonly cited as the main sources of information; caregivers also received information from other caregivers in the community. Caregivers’ motivations to seek MACV for their children were driven by personal awareness, engagements with trusted messengers, and perceived protective benefits of MACV against meningitis. Barriers to MACV and MCV2 uptake were linked to the unavailability of vaccines, immunization personnel not providing doses, knowledge gaps about the 15–18 month visit, practical constraints, past negative experiences, sociocultural influences, and misinformation, including misunderstanding about the need for MCV2. CONCLUSIONS: MACV and MCV2 uptake may be enhanced by addressing vaccination barriers and effectively communicating vaccination information and benefits through trusted messengers such as healthcare workers and other caregivers in the community. Educating healthcare workers to avoid withholding vaccines, likely due to fear of wastage, may help reduce missed opportunities for vaccination. Elsevier Science 2021-10-15 /pmc/articles/PMC8519392/ /pubmed/34579975 http://dx.doi.org/10.1016/j.vaccine.2021.09.038 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Aksnes, Brooke Noel Walldorf, Jenny A. Nkwenkeu, Sylvain F. Zoma, Robert L. Mirza, Imran Tarbangdo, Felix Fall, Soukeynatou Hien, Sansan Ky, Cesaire Kambou, Ludovic Diallo, Alpha Oumar Aké, Flavien H. Hatcher, Cynthia Patel, Jaymin C. Novak, Ryan T. Hyde, Terri B. Medah, Isaïe Soeters, Heidi M. Jalloh, Mohamed F. Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018 |
title | Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018 |
title_full | Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018 |
title_fullStr | Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018 |
title_full_unstemmed | Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018 |
title_short | Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018 |
title_sort | vaccination information, motivations, and barriers in the context of meningococcal serogroup a conjugate vaccine introduction: a qualitative assessment among caregivers in burkina faso, 2018 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519392/ https://www.ncbi.nlm.nih.gov/pubmed/34579975 http://dx.doi.org/10.1016/j.vaccine.2021.09.038 |
work_keys_str_mv | AT aksnesbrookenoel vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT walldorfjennya vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT nkwenkeusylvainf vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT zomarobertl vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT mirzaimran vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT tarbangdofelix vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT fallsoukeynatou vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT hiensansan vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT kycesaire vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT kambouludovic vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT dialloalphaoumar vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT akeflavienh vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT hatchercynthia vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT pateljayminc vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT novakryant vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT hydeterrib vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT medahisaie vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT soetersheidim vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 AT jallohmohamedf vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018 |